Sanofi Pasteur, KaloBios will develop drug for bacterial infections

01/11/2010 | American City Business Journals

Sanofi Pasteur formed a partnership with KaloBios Pharmaceuticals to develop KB-001, a treatment for Pseudomonas aeruginosa infections. The deal, worth potentially $290 million, will have Sanofi studying the compound for hospital-related infections, while KaloBios will conduct trials involving patients with cystic fibrosis and bronchiectasis.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health